COVID-19: Johnson & Johnson vaccinations to resume in the US following the recommendation of the panel US News


A U.S. medical panel has recommended resumption of use of Johnson & Johnson’s COVID-19 vaccine.

The advice came from advisors from the United States Centers for Disease Control and Prevention (CDC).

The vaccine was suspended last week by the CDC and the US Food and Drug Administration (FDA) after eight “serious” cases of rare blood clots related to low platelets. One person died.

The Johnson & Johnson vaccine, which is given as a single stab as opposed to two doses, has been given to nearly eight million people in the United States.

The vaccine is also known as Janssen vaccine – the name of the Belgian subsidiary of J & J.

It is now likely that the American government will quickly resume use of the sting – also known as the Janssen vaccine.

The advisory panel voted 10 to 4 to approve the use of the vaccine in adults. One member abstained.

Panelists who voted against said they were concerned that women may not be fully informed about the risks or that they may not be told that they could opt for a different vaccine.

All eight US cases of blood clots occurred in people under the age of 60, with the majority being women. They developed the condition within three weeks of the vaccination.

The FDA will update information about the risk and how to identify and treat the disease, Johnson & Johnson executives told the panel.

The EU Medicines Agency, EMA, said this week that the clots should be listed as “very rare” side effects However, the emphasized overall benefit outweighed the risks.

They were “very similar to the cases that came up with the Coronavirus Vaccine developed by AstraZeneca, “it added.

Johnson & Johnson chose it delay the rollout in Europe out of “fullness of caution” while US authorities investigated the clot.

The vaccine is not yet approved for use in the UK, but 30 million doses have been ordered.

A member of the US panel who recommended resumption of use of the shock said its benefits “significantly outweigh the risk from a population and an individual perspective.”

“It’s a new risk. It is admittedly an extremely small risk and smaller than many of the other risks we take every day,” said Dr. Beth Bell from the University of Washington.

Listen and follow the daily podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker

Johnson & Johnson Scientific Director Paul Stoffels said the panel’s advice was “an essential step to ensure that much-needed vaccinations continue to be safe for millions of people in the United States.”

He said the company will work with the CDC, FDA and European authorities “to ensure that this very rare event can be detected early and treated effectively”.

The EMA resumed the introduction of the earlier this month AstraZeneca vaccine for similar reports of rare blood clots.

This vaccine has yet to be approved in the United States.

Source link

Leave a Comment